Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group

[1]  A. Gajjar,et al.  Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N Benson,et al.  Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development , 2013, Clinical pharmacology and therapeutics.

[3]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[4]  B. Pollo,et al.  Histological variants of medulloblastoma are the most powerful clinical prognostic indicators , 2013, Pediatric blood & cancer.

[5]  Paul A. Northcott,et al.  DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies , 2013, Acta Neuropathologica.

[6]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[7]  N. Smoll,et al.  The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children , 2012, Journal of Clinical Neuroscience.

[8]  E. Hoffman,et al.  Neuro-oncology: Understanding the molecular complexity of medulloblastoma , 2012, Nature Reviews Neurology.

[9]  T. Björk-Eriksson,et al.  Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[11]  M. Mehta,et al.  Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[13]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[14]  Stefan M. Pfister,et al.  The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.

[15]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[16]  Scott L. Pomeroy,et al.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.

[17]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Roger E. Taylor,et al.  Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[21]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[22]  D. Figarella-Branger,et al.  Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  David W. Ellison,et al.  Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease , 2010, Acta Neuropathologica.

[24]  A. Gajjar,et al.  Role of high‐dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors , 2010, Pediatric blood & cancer.

[25]  Emmanuel Barillot,et al.  Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.

[26]  Axel Benner,et al.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[28]  Eric Bouffet,et al.  Core neurocognitive functions in children treated for posterior fossa tumors. , 2008, Neuropsychology.

[29]  T. Merchant,et al.  Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[31]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[32]  P. Burger,et al.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Mulhern,et al.  Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Frappaz,et al.  Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  U. Tabori,et al.  Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management , 2005, Cancer.

[38]  Mark L. Greenberg,et al.  Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Pietsch,et al.  Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.

[40]  Eric Bouffet,et al.  Change in neurocognitive functioning after treatment with cranial radiation in childhood. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Ellison,et al.  Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non‐Desmoplastic Medulloblastomas , 2003, Journal of neuropathology and experimental neurology.

[42]  D. Tait,et al.  Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Burger,et al.  Histopathologic grading of medulloblastomas , 2002, Cancer.

[44]  R. Packer,et al.  Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Krischer,et al.  Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N. Willich,et al.  Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. , 2000, International journal of radiation oncology, biology, physics.

[47]  L. Rorke,et al.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J L Kepner,et al.  Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Kool,et al.  Neogenin1 is a sonic hedgehog target in medulloblastoma and is necessary for cell cycle progression , 2014, International journal of cancer.

[50]  T. Zhou,et al.  Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. , 2013, Neuro-oncology.

[51]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[52]  S. Pfister,et al.  MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma , 2011, Acta Neuropathologica.